Bayer grabs $14.2B loan for Merck consumer buy; AZ research exec sells $1M in stock; Forest wins pediatric extension for Namenda;

@FiercePharma: Top-read special report Monday: The top 10 best-selling diabetes drugs of 2013. Report | Follow @FiercePharma

@TracyStaton: Trending now @FiercePharma: Novo Nordisk lays out plans to recruit 6,000 workers in R&D, production. Story | Follow @TracyStaton

@EricPFierce: #OSHA seeks $500,000 in penalties against #API maker that no longer exists but it was bad player when it did. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Pfizer puts the heat on Novartis with FDA MenB filing. Story from FierceVaccines | Follow @CarlyHFierce

@JustinHFierce: China-manufactured weight loss drug Sport Burner has Prozac in it, icymi, says @FDArecalls. Notification | Follow @JustinHFierce

> Bayer inked a $14.2 billion acquisition loan to back its buyout of Merck's ($MRK) consumer health business, with underwriting from bank of America Merrill Lynch, BNP Paribas and Mizuho Bank. Report

> AstraZeneca's ($AZN) CMO Briggs Morrison cashed in about $1 million worth of his shares in the company at a sale price of $73.79 each, lower than the price Pfizer ($PFE) had proposed to pay for the company. Report

> Forest Laboratories ($FRX) nabbed an additional 6 months of market control for its Alzheimer's medications Namenda and Namenda XR under the FDA's pediatric exclusivity program. Release

> Sanofi Pasteur's Gardasil vaccine against the human papillomavirus was approved in Europe as a preventive against anal cancer. Report

> Roche's ($RHHBY) blood cancer drug Gazyvaro won approval for use in previously untreated chronic lymphocytic leukemia patients in Switzerland. Release

> Sucampo Pharmaceuticals won backing from the U.K.'s cost-effectiveness watchdogs for its drug Amitiza as a treatment for chronic constipation. Report

Medical Device News

@FierceMedDev: Obesity device before FDA panel despite not meeting primary endpoints - FierceMedicalDevices. Story | Follow @FierceMedDev

@StacyALawrence: 3-D printer Materialise slated to price $104M IPO - FierceMedicalDevices. More | Follow @StacyALawrence

@MichaelGFierce: UPenn team combats #Parkinsons with immunotherapy that targets neuron killers. Story from FierceBiotechResearch | Follow @MichaelGFierce

@EmilyWFierce: Chrono Therapeutics tackles smoking cessation with programmable monitoring system. Article from FierceDrugDelivery | Follow @EmilyWFierce

> Medtronic merger could give Covidien execs an $80M payout. More

> Another FDA setback for Boston Scientific's Watchman stroke-fighting device. Story

> Lawmakers question FDA oversight of mobile medical apps as market booms. Article

Biotech News

@FierceBiotech: Meet the new Novartis: Slimmer structure, same R&D commitment. More | Follow @FierceBiotech

@JohnCFierce: For everyone in San Diego or coming next week: Killer weather, the kind that makes you want to move here. | Follow @JohnCFierce

@DamianFierce: Rebuffed in its attempt on AstraZeneca's cancer pipeline, Pfizer teams with Cellectis for immunotherapies of its own. Story | Follow @DamianFierce

> Cash-flush Sage swings for a $69M IPO to fund its CNS program. Article

> Big biotech booms while pharma payrolls wither. Report

> Insmed snags a surprise 'breakthrough' tag for its up-and-down antibiotic. News

Drug Delivery News

> Protein from a fatal fungus may offer up meningitis treatment. Story

> Chrono Therapeutics tackles smoking cessation with programmable monitoring system. More

> Proteasome inhibitor delivered with cancer-killing viruses enhances effect. Item

> 'Onion' drug delivery vehicle has concentric layers for consistent dosing. Article

Diagnostics News

> Sequenom enlists Quest to help market its prenatal test. More

> Alere gets FDA clearance for rapid influenza test. Story

> Natera puts its prenatal know-how toward cancer diagnostics. Article

> Enterome teams up with Mayo for gut diagnostics. Report

> Navidea bags expanded FDA nod for Lymphoseek. News

> Israeli bladder cancer Dx outfit raises $5M in financing. Item

Pharma Marketing News

> Fake patient story wins a real-life marketing award? Discuss. Story

> How to speak on social media? Finally, the FDA offers more specific clues. More

> Today's pharma reps need the skills of doctors, lawyers, beggars--but not thieves. Article

> Pfizer, Novartis square off for tussle in meningitis vaccine market. Story

> J&J recruits a Hispanic family to be its reps in the Hispanic market. News

And Finally... HIV pill for prevention? A debate. Report

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.